Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Maryland for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Maryland only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Maryland (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Yudhishtra Markan (NPI 1891762019)

Field	Value
Entity Type	Individual
Organization	Yudhishtra Markan
Address	305 Hospital Dr Fl 2
City	Glen Burnie
State	MD
ZIP	21061
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	March 7, 2006

Payer Source	Total Paid
Medicare	$3M
Medicaid	$0

Key Findings

This provider is a Hematology & Oncology Physician in GLEN BURNIE, MD with $3M in lifetime Medicare revenue and no Medicaid billing on file; the provider’s top 3 Medicare codes account for 60.3% of total Medicare revenue, indicating concentrated revenue drivers. The NPI was enumerated 2006-03-07 (~20 years ago), suggesting a long-tenured practice footprint in the Medicare market.

The code mix is dominated by high-cost oncology therapeutics and infusion services: J9271 (pembrolizumab) generates $1.1M (38.2% of Medicare revenue), Q5126 (bevacizumab-maly biosimilar) generates $326.2K (11.3%), and J0897 (denosumab) generates $313.2K (10.9%). These three oncology/supportive-care agents point to an operation focused on office-based cancer therapy and related bone-targeted supportive care rather than primary care or surgery.

Revenue concentration is high: with the top 3 codes representing 60.3% of Medicare revenue and a single code J9271 representing 38.2%, the practice’s financial performance is materially tied to utilization and reimbursement of a small set of oncology drugs. That concentration creates exposure to changes in drug mix, biosimilar uptake, or payer coverage policies for those specific agents.

Competitive standing varies by product and service. For its top drug J9271 the provider ranks #212 of 1841 (89th percentile; typical, unremarkable volume for this code), Q5126 ranks #3 of 29 (93th percentile; typical, unremarkable volume for this code), while J0897 ranks #388 of 10057 (96th percentile; notably above typical national volume for this code), indicating a mix of typical national participation for some high-cost drugs and above-typical use for others. Several administration and support codes are flagged as high-intensity versus peers (examples below), signaling relatively heavy utilization compared with national providers.

Clinical complexity and visit-level intensity are prominent: 99214 is a 99th percentile, extreme outlier and 99215 is also a 99th percentile, extreme outlier, while new-patient codes 99204 and 99205 are at elevated percentiles (95th). This pattern of high-level E/M coding is consistent with sustained management of complex oncology patients who require longer visits, significant decision-making, and frequent follow-up.

Chemotherapy and infusion throughput is a clear operational focus: 96413 (chemotherapy infusion) ranks in the 98th percentile and is labeled an extreme outlier, 96417 is a 99th percentile extreme outlier, and 96367 is a 99th percentile extreme outlier; G0498 (clinic-to-home infusion initiation) is notably above typical at the 97th percentile. Together these codes indicate substantial chair time, infusion nursing, and infusion-pump coordination capacity within the practice.

Supportive-care and ancillary therapy volumes are unusually high for several low-reimbursement, high-frequency injectables and antiemetics: J1627 (granisetron extended-release) is a 99th percentile extreme outlier, J0185 (aprepitant) is a 99th percentile extreme outlier, and J1449 (eflapegrastim) and J1437 (ferric derisomaltose) also appear among top revenue codes. Laboratory and phlebotomy codes (85025, 80053, 36415) rank at or above typical national volumes (including 85025 at the 98th percentile and 36415 at the 99th percentile), supporting an on-site diagnostics and infusion model.

Payer mix is effectively single-payer Medicare: the provider reports $3M in Medicare revenue and none for Medicaid, which suggests limited participation in Maryland Medicaid or limited Medicaid patient volume. That skew toward Medicare revenue has implications for population served, contract negotiation leverage with commercial plans versus state programs, and sensitivity to Medicare drug and infusion reimbursement trends.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

72 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	25,610	$40	$1.1M
Q5126	Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg	5,930	$60	$326.1K
J0897	Injection, denosumab, 1 mg	17,400	$20	$313.2K
J1437	Injection, ferric derisomaltose, 10 mg	11,000	$20	$176K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,630	$100	$162.8K
J1627	Injection, granisetron, extended-release, 0.1 mg	27,400	$10	$137K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	4,490	$30	$121.2K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	900	$110	$101.1K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	540	$150	$78.6K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	31,400	$1	$62.8K

Showing 1–10 of 72

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 72 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Maryland Distribution

Yudhishtra Markan — 11 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Maryland

Full comparison — all codes billed, vs. state median

72 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	15	60	15,000	$40	$787.6K
Q5126	2	10	7,000	$50	$382.5K
J1449	2	10	3,970	$30	$124.7K
J0897	27	340	3,600	$20	$114.4K
J0881	30	60	30,420	$1	$76.4K
J1437	5	50	2,800	$20	$75.1K
J3490	13	100	70	$450	$62.1K
J1627	1	10	7,400	$1	$59.7K
96413	7	230	200	$110	$29.6K
J9217	52	100	150	$130	$27.3K

Showing 1–10 of 72

Related Providers

Other providers that share a Tax Identification Number (TIN) with Yudhishtra Markan, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Mohammed Razvi	MD	Vascular & Interventional Radiology Physician	$3.4M	$0
Benjamin Lowentritt	MD	Urology Physician	$2.1M	$0
Gayatri Nimmagadda	MD	Hematology & Oncology Physician	$1.9M	$0
Tehmina Ali	MD	Anatomic Pathology Physician	$1.7M	$0
Robert Brookland	MD	Radiation Oncology Physician	$1.4M	$0
Enrico Giangeruso	VA	Anatomic Pathology & Clinical Pathology Physician	$1.4M	$0
Michael Isaacson	MD	Urology Physician	$1.3M	$0
Geoffrey Neuner	MD	Radiation Oncology Physician	$1.1M	$0
Michael Ballo	MD	Anatomic Pathology & Clinical Pathology Physician	$1.1M	$0
Arshia Soleimani	MD	Hematology & Oncology Physician	$1.1M	$0

Nearby Providers

Other providers in the same ZIP code as Yudhishtra Markan, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Associated Catholic Charities, Inc.	MD	Mental Health Clinic/Center (Including Community Mental Health Center)	$0	$22.9M
Kimmar Medical Associates	MD	Nursing Care Agency	$0	$15.8M
Elevate Recovery Centers LLC	MD	Substance Use Disorder Rehabilitation Clinic/Center	$0	$15.3M
People Encouraging People, Inc.	MD	Mental Health Counselor	$0	$15M
E J A L Health Services Inc	MD	Methadone Clinic	$0	$14.5M
Greenway Orthodontics LLC	MD	Orthodontics and Dentofacial Orthopedics Dentistry	$0	$12M
Michael Morris	MD	Diagnostic Radiology Physician	$12M	$0
Allcare Treatment Services, LLC	MD	Methadone Clinic	$272.6K	$10.3M
Baltimore Washington Emergency Physicians, Inc.	MD	Emergency Medicine Physician	$0	$10.3M
Omni House Inc	MD	Mental Illness Community Based Residential Treatment Facility	$0	$10.1M

Yudhishtra Markan — Billing Profile & Reimbursement Data

Sign up for Yudhishtra Markan — Billing Profile & Reimbursement Data policy alerts

Yudhishtra Markan — Billing Profile & Reimbursement Data

Sign up for Yudhishtra Markan — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References